Cargando…

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol

RATIONALE & OBJECTIVE: Mineral and bone disorder in chronic kidney disease (CKD) is associated with progression of coronary artery calcification (CAC). Mineral and bone disorder often is treated with calcitriol and other vitamin D receptor activators, including paricalcitol, agents that may have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anis, Karim H., Pober, David, Rosas, Sylvia E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406841/ https://www.ncbi.nlm.nih.gov/pubmed/32775985 http://dx.doi.org/10.1016/j.xkme.2020.05.009

Ejemplares similares

Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD
por: Ramakrishnan, Madhuri, et al.
Publicado: (2020)

Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
por: Riccio, Eleonora, et al.
Publicado: (2015)

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl
por: Bothou, Christina, et al.
Publicado: (2018)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Vitamin D, the Vitamin D Receptor, Calcitriol Analogues and Their Link with Ocular Diseases
por: Caban, Miłosz, et al.
Publicado: (2022)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Chondro/Osteoblastic and Cardiovascular Gene Modulation in Human Artery Smooth Muscle Cells That Calcify in the Presence of Phosphate and Calcitriol or Paricalcitol
por: Shalhoub, V, et al.
Publicado: (2010)

The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control
por: Cozzolino, Mario, et al.
Publicado: (2011)

“Calcitriol” Is Not Synonymous with “Vitamin D”
por: Kimball, Samantha M., et al.
Publicado: (2012)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

PTH suppression by calcitriol does not predict off‐target actions in experimental CKD
por: Svajger, Bruno A., et al.
Publicado: (2020)

The vitamin D analogue paricalcitol attenuates hepatic ischemia/reperfusion injury through down-regulation of Toll-like receptor 4 signaling in rats
por: Kim, Min Sung, et al.
Publicado: (2016)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
por: Ussif, Amin, et al.
Publicado: (2018)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

Coronary artery calcification score and common iliac artery calcification score in non‐dialysis CKD patients
por: Mizuiri, Sonoo, et al.
Publicado: (2018)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
por: Xie, Yifeng, et al.
Publicado: (2017)

Progression of Medial Arterial Calcification in CKD
por: Manzoor, Shumila, et al.
Publicado: (2018)

Abdominal aortic calcification in patients with CKD
por: Peeters, Mieke J., et al.
Publicado: (2016)

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection
por: Duplancic, Darko, et al.
Publicado: (2013)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
por: De Nicola, Luca, et al.
Publicado: (2012)

Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
por: Trummer, Christian, et al.
Publicado: (2017)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Calcitriol and non-calcemic vitamin D analogue, 22-oxacalcitriol, attenuate developmental and pathological choroidal vasculature angiogenesis ex vivo and in vivo
por: Merrigan, Stephanie L., et al.
Publicado: (2020)

Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?
por: Pasquali, Marzia, et al.
Publicado: (2015)

Effects of Vitamin D(3) and Paricalcitol on Immature Cardiomyocytes: A Novel Role for Vitamin D Analogs in the Prevention of Cardiovascular Diseases
por: Pacini, Stefania, et al.
Publicado: (2013)

Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease
por: de Boer, Ian H., et al.
Publicado: (2012)

Magnesium in CKD: more than a calcification inhibitor?
por: Floege, Jürgen
Publicado: (2014)

Targeting Vascular Calcification in CKD: Time to Redraw the Map
por: O'Neill, W. Charles
Publicado: (2023)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Coronary artery calcification in CKD-5D patients is tied to adverse cardiac function and increased mortality
por: Anaya, Paul, et al.
Publicado: (2016)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Effects of calcitriol on random skin flap survival in rats
por: Zhou, Kai-liang, et al.
Publicado: (2016)

Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
por: Larsen, Thomas, et al.
Publicado: (2013)

The Use of Vitamin D3 (Calcitriol) for Improving Autologous Fat Graft Retention
por: Wang, Sheri S., et al.
Publicado: (2019)

Bioconversion of vitamin D(3) to bioactive calcifediol and calcitriol as high-value compounds
por: Wang, Zheyi, et al.
Publicado: (2022)

Vitamin-D receptor agonist calcitriol reduces calcification in vitro through selective upregulation of SLC20A2 but not SLC20A1 or XPR1
por: Keasey, M. P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_endk80lpci3kdj523l0hsk2rpg